Moxaverine

Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,^[1] and on its influence on the rheological properties of red blood cells.^[2]

Moxaverine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A03AD30 (WHO)
Identifiers
IUPAC name 1-Benzyl-3-ethyl-6,7-dimethoxyisoquinoline
CAS Number	10539-19-2 Y
PubChem CID	70882
ChemSpider	64045 N
UNII	P3P08Y1XJ4
KEGG	D07089 Y
CompTox Dashboard (EPA)	DTXSID6057613
ECHA InfoCard	100.031.003
Chemical and physical data
Formula	C20H21NO2
Molar mass	307.393 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3
InChI InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3 N Key:MYCMTMIGRXJNSO-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.^[3] The ocular efficacy of moxaverine has been explored in the clinic.^[4]